Genzyme: Engineering the Market for Orphan Drugs

Genzyme: Engineering the Market for Orphan Drugs: "Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures."